# FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia

> **NCT02244255** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1993 (actual)

## Conditions studied

- Prostatic Hyperplasia

## Interventions

- **DRUG:** FLOMAX® capsules
- **DRUG:** Ascending doses of HYTRIN® capsules

## Key facts

- **NCT ID:** NCT02244255
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-08
- **Primary completion:** 2000-06
- **Final completion:** —
- **Target enrollment:** 1993 (ACTUAL)
- **Last updated:** 2014-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02244255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02244255, "FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02244255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*